Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients.
Liontos M, Terpos E, Kunadis E, Zagouri F, Briasoulis A, Skafida E, Fiste O, Markellos C, Andrikopoulou A, Gumeni S, Kaparelou M, Koutsoukos K, Gavriatopoulou M, Kastritis E, Trougakos IP, Dimopoulos MA.
Liontos M, et al. Among authors: zagouri f.
Prostate Cancer Prostatic Dis. 2022 Mar;25(1):117-118. doi: 10.1038/s41391-021-00455-9. Epub 2021 Oct 9.
Prostate Cancer Prostatic Dis. 2022.
PMID: 34628475
Free PMC article.